Previous 10 | Next 10 |
home / stock / brrgf / brrgf news
- Acute Myeloid Leukaemia (AML): Preliminary Phase II clinical shows promising efficacy for bemcentinib in combo with low-intensity chemo in elderly AML patients unfit for intensive therapy - Non small cell lung cancer (NSCLC): Phase II clinical data continues to show promising clinical ac...
Rigel Pharmaceuticals' ( RIGL ) Tavalisse, launched in mid-2018, is experiencing sales growth but competitors exist that could potentially reduce peak sales. RIGL's partnered pipeline provides a source of potentially good news to offset any bad news regarding advances from RIGL's competitors...
BerGenBio ASA ( OTCPK:BRRGF ) is due to presents data today at the European Hematology Association showing significant efficacy in a Phase II clinical trial evaluating bemcentinib in combination with low-dose cytarabine as a potential new treatment regimen for AML patients unfit f...
OSLO, Norway , June 14, 2019 /PRNewswire/ -- Two posters to be presented at the 2019 annual congress of the European Hematology Association on 14th June Phase II trial evaluating bemcentinib in combination with low-intensity chemotherapy in elderly acute myeloid leukaemia (AML) patie...
BERGEN, Norway , May 15, 2019 /PRNewswire/ -- Two peer reviewed abstracts on Phase II clinical data with bemcentinib accepted for presentation at ASCO 2019 Non-Small-Cell Lung Cancer (NSCLC) trial of bemcentinib in combination with pembrolizumab, data to be presented includes safety...
Phase II, Simon two-stage trial evaluating bemcentinib and KEYTRUDA in previously treated NSCLC post chemotherapy (Cohort A, NCT03184571) First stage previously met efficacy endpoint Second stage enrolled a further 24 patients for a total of 48; efficacy and biomarker data updat...
BergenBio ( OTCPK:BRRGF ): Q1 GAAP EPS of -NOK0.81. More news on: BerGenBio ASA, Earnings news and commentary, Healthcare stocks news, , Read more ...
- Advanced leukaemia (AML/MDS): Phase II trial fully recruited and combination trial with low-intensity chemotherapy meets efficacy endpoint in hard to treat relapsed / refractory (R/R) leukaemia - Advanced lung cancer (NSCLC): Additional cohort added in trial of bemcentinib in combinat...
- Phase II data in AML combining bemcentinib with low-dose chemotherapy and NSCLC combining with KEYTRUDA - Accepted for presentation at ASCO in June 2019 OSLO, Norway , April 23, 2019 /PRNewswire/ -- BerGenBio ASA (OSE: BGBIO) a clinical-stage biopharmaceuti...
BERGEN, Norway , April 9, 2019 /PRNewswire/ -- BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company focused on developing a pipeline of first-in-class drug candidates targeting AXL kinase to treat aggressive diseases including immune-evasive and therapy resistant cancers,...
News, Short Squeeze, Breakout and More Instantly...
Brent Resources Group Ltd Company Name:
BRRGF Stock Symbol:
OTCMKTS Market:
Brent Resources Group Ltd Website:
Bergenbio Presents Encouraging Updated Preliminary Data From Phase Ii Study In Relapsed Aml Patients At Eha Virtual Meeting Encouraging updated preliminary survival data more than double standard of care reported in relapsed AML patients PR Newswire BERGEN, Norway ...
BerGenBio Presents Updated Clinical Data From Two Phase II Studies Of Bemcentinib in AML and MDS Patients At Ash 2020 BERGEN, Norway , Dec. 6, 2020 /PRNewswire/ -- BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL...
BerGenBio Presents Phase II Bemcentinib Combination Study in NSCLC at Annual SITC Meeting PR Newswire BERGEN, Norway, Nov. 11, 2020 BERGEN, Norway , Nov. 11, 2020 /PRNewswire/ -- BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing...